Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
9MW-3011 in Beta-Thalassemia: NCT06772766 Clinical Landscape Report 2026
16 September 2026
NCT06772766 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Domvanalimab in Carcinoid Tumor: NCT06790706 Clinical Landscape Report 2026
16 September 2026
NCT06790706 clinical landscape for Carcinoid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dupilumab in Severe asthma: NCT06818019 Clinical Landscape Report 2026
16 September 2026
NCT06818019 clinical landscape for Severe asthma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
INS-1201 in Muscular Dystrophy, Duchenne: NCT06817382 Clinical Landscape Report 2026
16 September 2026
NCT06817382 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PGN-EDO51 in Muscular Dystrophy, Duchenne: NCT06833931 Clinical Landscape Report 2026
16 September 2026
NCT06833931 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
E-EDV-D682 in Solid tumor: ACTRN12625000203459 Clinical Landscape Report 2026
16 September 2026
ACTRN12625000203459 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ivonescimab in Malignant Pleural Mesothelioma: NCT06840834 Clinical Landscape Report 2026
16 September 2026
NCT06840834 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Forazapadin in Muscular Dystrophy, Duchenne: NCT06867107 Clinical Landscape Report 2026
16 September 2026
NCT06867107 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ivonescimab in Malignant Pleural Mesothelioma: NCT06875076 Clinical Landscape Report 2026
16 September 2026
NCT06875076 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LE-051 in Muscular Dystrophy, Duchenne: NCT06900049 Clinical Landscape Report 2026
16 September 2026
NCT06900049 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Lung Cancer: NCT06885697 Clinical Landscape Report 2026
16 September 2026
NCT06885697 clinical landscape for Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bemiltenase alfa in Hemophilia: NCT06922045 Clinical Landscape Report 2026
16 September 2026
NCT06922045 clinical landscape for Hemophilia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.